wiz/zbtb7a degrader bms-986470
Generic: WIZ/ZBTB7A Degrader BMS-986470
wiz/zbtb7a degrader bms-986470: 1 clinical trial tracked.
wiz/zbtb7a degrader bms-986470 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about wiz/zbtb7a degrader bms-986470, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Primary endpoint: Number of participants with adverse events (AEs)
InterventionalRandomizedquadruple224 targetStarted 2024-07Completion 2027-1132 sites · Canada, France, Italy, United Kingdom…Bristol-Myers Squibb